- Six dead after floods in central Japan: media
- Australian golf prodigy suffers career-threatening eye injury
- Gaza hospital a symbol of the ruin of war
- October 7: how Israel's deadliest day unfolded
- Bibles, sneakers, silver coins: Trump's merch for sale
- Met Opera opens season with tech-heavy 'Grounded'
- Colombia's Inirida flower: from 'weed' to emblem for UN meeting
- Colombia rebel group imposes control in restive coca zone
- Rams fight back to upset 49ers, Cowboys lose again
- Sri Lankan leftist leader to take office after landslide election win
- 300-kilo WWI bomb removed in Belgrade
- Zelensky in US to explain war plan to Biden, Harris, Trump
- 'Atrocious' Sudan war pushing refugees further afield: UNHCR chief
- 'Convergence' growing on global plastics treaty: UN environment chief
- MLB White Sox fall to Padres to match one-season loss mark
- All-Australian Ripper squad captures LIV Golf team crown
- Barnier promises compromise from France's embattled new govt
- Zelensky arrives in US to explain war plan to Biden
- Barca rout Villarreal but Ter Stegen hurt, Atletico draw at Rayo
- Darnold shines for Vikings, Steelers and Eagles win
- Atletico held to draw at Rayo Vallecano
- Marseille stun Lyon with 95th-minute winner after early red card
- Gabbia ends AC Milan's derby pain with late winner against Inter
- Surging Ko claims LPGA Queen City crown in spectacular style
- 'Impossible': Alcaraz shoots down Federer comparisons after Laver Cup win
- Scholz's party beats far-right AfD in east German state vote
- Verstappen says 'silly' swearing row could hasten F1 exit
- Calls for Israel and Hezbollah to step back from the abyss
- Israel and Hezbollah urged to avoid 'catastrophe'
- Colombia battles fires as drought fuels Latin American flames
- Pressure piles on new French government from day one
- Arteta proud as Arsenal salvage point from 'impossible' task
- Barca rout Villarreal in thriller but Ter Stegen hurt
- Roma stroll past Udinese as fans protest De Rossi sacking
- Horschel outduels McIlroy to win PGA Championship play-off
- Audiences summon 'Beetlejuice' to top of N. America box office for third week
- Stones salvages point for Man City against 10-man Arsenal
- Egypt fears 'all out' regional war: foreign minister to AFP
- Last-gasp Boniface gives Leverkusen victory, Stuttgart outclass Dortmund
- Scholz's party beats far-right AfD in east German state vote: projections
- Olympic champion Evenepoel retains world title in 'toughest time trial'
- Horschel's eagle beats McIlroy in PGA Championship play-off
- Mourners at commander's funeral express loyalty to Hezbollah
- Norris hails his 'mega' McLaren after dominant win at Singapore
- Monaco beat Le Havre to join PSG at the top of Ligue 1
- Scholz's party narrowly leads far-right AfD in east German state vote: exit polls
- New leftist president vows to 'rewrite Sri Lankan history'
- UN adopts pact to tackle volatile future for mankind
- Leclerc hails Ferrari fightback from torrid Singapore GP qualifying
- Belgian Evenepoel retains world title in 'toughest time trial'
US FDA approves Wegovy to cut risk of heart problems
The US Food and Drug Administration has given the green light for a popular anti-obesity drug to be used to prevent serious heart conditions for the first time, in a move likely to expand insurance coverage.
Wegovy, produced by Danish pharmaceutical giant Novo Nordisk, was approved "to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight," the FDA said in a statement.
The FDA's decision could be a game changer for the approximately 70 percent of American adults who it says are either obese or overweight, by potentially expanding the pool of people eligible to have their insurance cover these expensive but effective drugs.
"This patient population has a higher risk of cardiovascular death, heart attack and stroke," the director of the FDA's Division of Diabetes, Lipid Disorders and Obesity, said in a statement.
"Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health," he added.
The recent surge in popularity of anti-obesity drugs including Wegovy and Ozempic, which mimic a gut hormone to suppress appetite, has padded the profits of the companies that make them.
In fact, Novo Nordisk, which produces both Wegovy and Ozempic, has been so profitable that it has helped to keep the Danish economy afloat, according to Danske Bank.
The pharmaceutical giant's success "is pushing overall activity levels up, while much of the rest of industry and housing construction have contracted," Heidi Schauman, the bank's global head of research, wrote in a note earlier this week.
Novo Nordisk's head of development, Martin Holst Lange, welcomed the FDA's announcement, calling it "an important milestone for people living with obesity and cardiovascular disease."
Wegovy "has the potential to prolong lives by addressing some of the leading causes of preventable deaths by reducing the risks of cardiovascular events," he said in a statement.
L.Harper--AMWN